A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation  by Robinson, Megan J. et al.
A constitutively active and nuclear form of the MAP kinase ERK2
is sufficient for neurite outgrowth and cell transformation 
Megan J. Robinson*, Stephen A. Stippec*, Elizabeth Goldsmith†, 
Michael A. White‡ and Melanie H. Cobb*
Background: Mitogen-activated protein (MAP) kinases are ubiquitous
components of many signal transduction pathways. Constitutively active
variants have been isolated for every component of the extracellular-signal-
regulated kinase 1 (ERK1) and ERK2 MAP kinase pathway except for the 
ERK itself.
Results: To create an activated ERK2 variant, we fused ERK2 to the low
activity form of its upstream regulator, the MAP kinase kinase MEK1. The ERK2
in this fusion protein was active in the absence of extracellular signals.
Expression of the fusion protein in mammalian cells did not activate
endogenous ERK1 or ERK2. It was sufficient, however, to induce activation of
the transcription factors Elk-1 and AP-1, neurite extension in PC12 cells in the
absence of nerve growth factor, and foci of morphologically and growth-
transformed NIH3T3 cells, if the fusion protein was localized to the nucleus. A
cytoplasmic fusion protein was without effect.
Conclusions: Activation of ERK2 is sufficient to cause several transcriptional
and phenotypic responses in mammalian cells. Nuclear localization of activated
ERK2 is required to induce these events.
Background
In eukaryotic cells, activation of ubiquitous mitogen-acti-
vated protein (MAP) kinases contributes to cell-type and
ligand-specific responses [1,2]. MAP kinase cascades
contain a conserved core of enzymes known as the MAP
kinase module, which consists of a MAP kinase, a MAP
kinase kinase or MEK, and a MEK kinase. The best char-
acterized MAP kinase module contains extracellular-
signal-regulated kinase 1 (ERK1) and ERK2. The
functions of the ERK pathway, containing the upstream
regulators MEK1 and MEK2 and Raf isoforms, are diverse
but have been associated with cell proliferation and differ-
entiation [1,2].
Constitutively active MAP kinase variants would be valu-
able reagents to define the functions of these kinases in
physiological processes. Unfortunately, no such molecules
have been described to date. Genetic screens have not
yielded gain-of-function MAP kinase mutants of use in
mammalian systems. For example, the Drosophila seven-
maker mutant has only 2–3-fold greater activity than
unphosphorylated wild-type ERK in Drosophila [3]. ERK2
is normally activated more than 1000-fold by dual phos-
phorylation on threonine and tyrosine [4]. In mammalian
cells, the sevenmaker mutant still requires activation by
MEKs and does not have increased basal activity; thus,
this mutant cannot be used as a constitutive kinase in
mammalian cells [5].
Attempts to make structure-based site-directed mutants
of ERK2 with constitutive activity have been unsuccess-
ful [6] (M.J.R., M.H.C. and E.G., unpublished observa-
tions). Recently, the structure of phosphorylated, active
ERK2 was solved [7]. Comparison of the high and low
activity structures [8] suggested no obvious strategy for
creating a constitutively active ERK2 by mutagenesis,
because of the global reorganization of domains that
occurs in the structure upon ERK2 activation and phos-
phorylation. Thus, to create a constitutively active ERK2,
we fused ERK2 as a single polypeptide to its upstream
activator MEK1. The fusion produced an ERK2 that was
constitutively active in the absence of upstream signals.
MEK1 in the fusion protein had no effect on endogenous
ERKs. We were then able to direct active ERK2 to differ-
ent subcellular compartments and examine its effects on
several biological processes. We show that active ERK2
induced the phosphorylation of Elk-1, the activation of
the transcription factors AP-1 and Elk-1, and was suffi-
cient to cause both neurite outgrowth in PC12 cells and
transformation of NIH3T3 cells. These functions of
ERK2 were dependent on the subcellular localization of
the active enzyme.
Results
Expression and activity of an ERK2–MEK1 fusion protein
We reasoned that coupling ERK2 to its upstream regulator
MEK1 might increase ERK phosphorylation, resulting in
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high levels of dually phosphorylated active ERK2. To
create an ERK2–MEK1 fusion protein, a linker of 10
amino acids, composed of an alternating copolymer of glu-
tamate and glycine, was connected to the carboxyl termi-
nus of rat ERK2, and the coding sequence of human
MEK1 was fused in-frame. The linker provided a flexible
region between the two protein domains that was of suffi-
cient length to allow proper folding (Figure 1). Vector
sequence from the original MEK1 construct was included.
Thus, the sequence between ERK2 and MEK1 is
EGEGEGEGEGSGGVGSALPGSK (in single-letter
amino acid code).
The ERK2–MEK1 fusion protein and other fusion pro-
teins described below were expressed as stable, full-
length proteins in mammalian cells (Figure 2a) and no
cleavage of the molecules occurred (see Supplementary
material published with this paper on the internet). The
immunoprecipitated ERK2–MEK1 fusion protein was at
least 50-fold more active than either a vector-alone control
or an inactive ERK2 fusion protein, K52R-ERK2–MEK1,
which was expressed to the same extent (Figure 2). Muta-
tion of K52 to arginine reduces ERK2 catalytic activity by
more than 99% [9]. In comparison, when ERK2 and
MEK1 were coexpressed as separate proteins, the ERK2
activity recovered was less than 10% of that of ERK2 in
the fusion protein (data not shown). Replacing wild-type
MEK1 in the fusion protein with a kinase-dead form
resulted in a fusion protein with activity no greater than
the vector-alone control (see Supplementary material).
The MEK1/2 inhibitor PD098059 [10] had no effect on
the activity of the active ERK2 fusion protein (data not
shown), suggesting that basal activity of endogenous Raf
was not required for activating ERK2–MEK1. Dephos-
phorylating the fusion protein reduced its activity and
incubating it under phosphorylating conditions restored its
activity, indicating that ERK2 in the fusion protein is acti-
vated by phosphorylation (see Supplementary material).
We wished to determine if endogenous ERKs were sub-
strates for ERK2–MEK1. Endogenous ERK1 and ERK2
were not activated even at the highest level of
ERK2–MEK1 expression, although they were activated
10-fold by epidermal growth factor (EGF) or phorbol ester
(PMA), as shown either by blotting with an antibody
against active ERK (Figure 3a) or by immunoprecipitation
and immune-complex kinase assay (Figure 3b). Hemag-
glutinin (HA)-tagged ERK2 that was cotransfected with
the ERK2–MEK1 fusion protein was activated no more
1142 Current Biology, Vol 8 No 21
Figure 1
Schematic of the fusion protein design. The Glu–Gly linker allows
correct protein folding, and the ERK2 becomes phosphorylated
(ERK2-P). See text for details.
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Figure 2
Expression and activity of the ERK2–MEK1
fusion protein and two mutants. Cells were
transfected with 1 or 10 µg of the indicated
fusion protein and (a) a western blot of the
lysates was performed with an anti-Myc
antibody to detect expression of the proteins.
Lysates without fusion protein were loaded in
the control lane. (b) Lysates were
immunoprecipitated with the anti-Myc
antibody and immune-complex kinase assays
were performed with the substrate myelin
basic protein (MBP). Different amounts of the
kinase assays were loaded on the gel as
follows: control, 40 µl; ERK2–MEK1, 20 µl;
ERK2–MEK1-LA, 5 µl; and KR-ERK2–MEK1,
40 µl. Exposure time of the gel to film was
1 min at room temperature. Similar results
were found in multiple experiments in both
293 cells and PC12M cells.
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than twofold (data not shown). Thus, the MEK1
expressed in the fusion protein specifically acts on the
ERK it is fused with and does not activate endogenous
ERK or ERK regulators.
Subcellular localization of the ERK2–MEK1 fusion protein
Upon phosphorylation by MEK, a fraction of ERK2
translocates to the nucleus where it can then phosphory-
late nuclear substrates [11–15]. MEK1, however, contains
a leucine-rich nuclear export sequence, which causes it to
retain a cytoplasmic localization even in stimulated cells
[16,17]. Given the opposing signals on ERK2 and MEK1,
we wanted to determine the subcellular localization of the
ERK2–MEK1 fusion protein. Indirect immunofluores-
cence staining of 293 cells revealed that it was localized in
the cytoplasm (Figure 4a). Thus, it appeared that either
the MEK1 export sequence was dominant, or that ERK2
could no longer translocate properly. To distinguish
between these possibilities, the four leucines in MEK1
that are crucial for nuclear export [16] were mutated to
alanine. This mutant MEK1 was substituted for wild-type
MEK1 in the fusion construct, producing ERK2–MEK1-
LA (Figure 2a). In transiently transfected cells, this fusion
protein had 5–10-fold higher kinase activity than equiva-
lent amounts of wild-type ERK2–MEK1 (Figure 2b),
whereas in stably transfected cells both fusion proteins
had equivalent activities (data not shown). The differen-
tial activity of ERK2–MEK1-LA was not surprising,
because Mansour et al. [18,19] have shown that the region
in MEK1 containing the export sequence is also important
in controlling MEK1 activity. Like ERK2–MEK1,
ERK2–MEK1-LA had no effect on the activity of endoge-
nous ERK1/2 (Figures 3a,b). Neither of these fusion pro-
teins activated the endogenous p38 or Jun N-terminal
kinase (JNK)/stress-activated protein kinase (SAPK) (data
not shown).
Indirect immunofluorescence staining of 293 cells
expressing ERK2–MEK1-LA showed that the fusion
protein was localized to the nucleus (Figure 4b); even in
cells expressing low amounts, the majority was in the
nucleus. Thus, active ERK2 created via fusion to MEK1
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Figure 3
Effect of the ERK2–MEK1 fusion proteins on
endogenous ERK1 and ERK2. Control cells
were treated with either EGF for 5 min or
PMA for 15 min. Cells were transfected with
the indicated fusion proteins and (a) a
western blot of the lysates was performed
with an antibody that recognizes the doubly
phosphorylated active forms of ERK1/2.
(b) Lysates were immunoprecipitated with the
A249 antibody that recognises endogenous
ERK1 and ERK2. Immune-complex kinase
assays were then performed using MBP as
substrate. Similar results were found in
multiple experiments in both 293 cells and
PC12M cells. (c) Expression and activity of
the ERK2–MEK1-SDSE fusion protein.
Expression of the protein is shown in the Myc
blot of the top panel, immune-complex kinase
assays of the fusion are shown in the middle
panel, and immune-complex kinase assays of
endogenous ERK1/2 in the presence of the
fusion are shown in the bottom panel.
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Figure 4
Indirect immunofluorescence of ERK2–MEK1
and ERK2–MEK1-LA transiently expressed in
293 cells. (a) An anti-Myc antibody was used
to visualize the ERK2–MEK1 fusion, and DAPI
was used to visualize the nuclei in the same
cells. (b) Localization of the ERK2–MEK1-LA
fusion. The arrow points to the cell stained
with the anti-Myc antibody in the left-hand
panel.
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can be directed to different subcellular compartments
without affecting the activity of endogenous ERKs.
ERK2–MEK1-LA phosphorylates Elk-1 and induces AP-1-
and Elk-1-dependent gene expression
To determine whether ERK2–MEK1 and ERK2–MEK1-
LA could phosphorylate a known ERK2 substrate, we
examined the phosphorylation of the ternary complex
factor Elk-1 [20–24]. Elk-1 was expressed in 293 cells
either alone or together with an activated mutant of the
GTPase Ras, RasV12, or with ERK2–MEK1 or
ERK2–MEK1-LA. Elk-1 phosphorylation was monitored
using an antibody that recognizes Elk-1 only when it is
phosphorylated on Ser383, a site of ERK phosphorylation
that is important for transactivating activity [20,22]. Only
RasV12 and the nuclear fusion protein ERK2–MEK1-LA
caused an increase in Elk-1 phosphorylation (Figure 5a).
The cytoplasmic variant ERK2–MEK1 did not. As confir-
mation, a large band shift in the position of Elk-1 on the
gel occurred when it was coexpressed with ERK2–MEK1-
LA but not when it was coexpressed with ERK2–MEK1
(Figure 5a, top panel). It is unlikely that the difference in
the activities of the two fusion proteins can account for
their differing abilities to phosphorylate Elk-1 as we show
below in our physiological assays that comparable activi-
ties of the two fusions still produce the same results.
Consistent with the above results, ERK2–MEK1-LA but
not ERK2–MEK1 induced significant expression of an Elk-
1-dependent luciferase reporter (Figure 6a). The cytoplas-
mic ERK2–MEK1 fusion protein displayed a limited ability
to activate Elk-1-mediated transcription. This is likely to be
due to the overexpression of Elk-1 as a Gal–Elk-1 fusion in
these assays resulting in a small amount of cytoplasmic 
Elk-1. ERK2–MEK1 did not induce expression of an AP-1-
dependent luciferase reporter (Figure 6a) or a serum
response element (SRE) reporter (data not shown) even
when 20 µg of plasmid were transfected, whereas
ERK2–MEK1-LA induced expression from both reporters.
Because the activity of ERK2–MEK1-LA was higher than
that of ERK2–MEK1, we compared different amounts of
plasmid expressing ERK2–MEK1-LA to test the effects of
small amounts of this protein on AP-1 activity (Figure 6b).
Using 5 µg of plasmid, ERK2–MEK1-LA stimulated AP-1
activity by 30-fold. Even when only 10 ng of plasmid were
introduced, ERK2–MEK1-LA stimulated AP-1 activity by
6-fold. Under these conditions, the amount of fusion protein
expressed could no longer be detected by western blotting.
Thus, the nuclear fusion protein is a potent AP-1 activator.
On the other hand, neither ERK2 fusion protein activated
an NFκB-dependent reporter more than a few fold (data
not shown). As a control for the ability of the cytoplasmic
fusion protein to phosphorylate substrates, we cotrans-
fected cells with constructs expressing the substrate ribo-
somal S6 kinase (Rsk) and various fusion proteins
(Figure 5b). Rsk was activated by ERK2–MEK1 to the
same extent as by phorbol ester, demonstrating that
ERK2–MEK1 has intracellular activity. Interestingly,
ERK2–MEK1-LA was a more potent Rsk activator, which
may reflect the fact that Rsk also cycles between the cyto-
plasm and the nucleus [11].
Effect of ERK2–MEK1 fusion proteins on PC12 cell
differentiation
Differentiation of PC12 cells correlates with ERK activa-
tion, and it has been proposed that the Ras–Raf pathway,
1144 Current Biology, Vol 8 No 21
Figure 5
(a) Phosphorylation of Elk-1 by the
ERK2–MEK1 fusion proteins. Cells were
transfected with the indicated fusion protein
and lysates blotted with an anti-Elk-1
antibody. In the double transfections, 10 µg
Elk-1 was used (top panel). The blot was
stripped and reprobed with an antibody that
recognizes the phosphoserine383 form of
Elk-1 (bottom panel). Similar results were
found in two other independent experiments.
(b) Phosphorylation of Rsk by fusion proteins.
A Rsk-encoding plasmid (10 µg) was
transfected alone, with 10 µg fusion protein
DNAs, or with 2 µg ERK2 plasmid. Rsk was
immunoprecipitated 48 h after transfection
and immune-complex kinase assays were
performed using glutathione-S-transferase
(GST)–S6 as substrate. Results shown are an
average of two experiments.
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and therefore ERK, is sufficient to induce this phenotype
[25–27]. To test whether ERK activity is sufficient for dif-
ferentiation, we examined the consequences of expressing
ERK2–MEK1 and ERK2–MEK1-LA in PC12 cells.
Transfected cells were scored for neurite formation after
48–96 hours in the absence or presence of 50 ng/ml nerve
growth factor (NGF).
ERK2–MEK1-LA was comparable to NGF in its ability to
stimulate neurite outgrowth (Figure 7). Thus, expression
of an activated ERK2 variant targeted to the nucleus is
sufficient to promote neurite extension in the absence of
NGF. In contrast, ERK2–MEK1, which was retained in
the cytoplasm, caused no more neurite extension than a
vector control. In addition, neither MEK1-LA nor ERK2
alone induced neurite outgrowth (Figure 7). A fusion
protein containing ERK2 linked to a constitutively active
form of MEK1 (S118D, S222E) [18], termed
ERK2–MEK1-SDSE, produced an ERK2 that was
slightly more active than that in ERK2–MEK1-LA.
ERK2–MEK1-SDSE, although cytoplasmic, had an
increased ability to induce neurites (Figure 7) compared
with ERK2–MEK1. The ERK2–MEK1-SDSE fusion
protein activated endogenous ERKs to a modest extent,
around sevenfold (Figure 3c), however. Thus, its ability to
produce some PC12 cell differentiation is likely to be due
to the activation of endogenous ERKs.
Because MEK1-LA had an increased ability to activate
ERK2 relative to wild-type MEK1 in the context of the
fusion proteins, we wanted to compare the function of
equivalent amounts of fusion protein activity on neurite
extension. Smaller amounts of ERK2–MEK1-LA DNA
were transfected compared with ERK2–MEK1 so that
comparable ERK2 activities were produced. Even under
these conditions, ERK2–MEK1-LA still produced neu-
rites, whereas the cytoplasmic fusion did not.
Finally, we constructed a fusion protein that contained
K52R ERK2 fused to MEK1-LA, to examine the effects
of a kinase-inactive ERK2 in the nucleus. Like KR-
ERK2–MEK1, KR-ERK2–MEK1-LA had no kinase
Research Paper  Constitutively active ERK2 Robinson et al.    1145
Figure 6
(a) Activation of AP-1-dependent and Elk-1-
dependent transcription by the ERK2–MEK1
fusion proteins and by RasV12. Values are
given as luciferase activity relative to control
transfections and are normalized to
β-galactosidase. Standard deviation of three
or four independent experiments is shown,
and each individual experiment was performed
in duplicate. (b) The effect of titration of the
ERK2–MEK1-LA plasmid on AP-1-dependent
transcription. The experiment was performed
as in (a) except that the amount of fusion
plasmids was varied as indicated. The inset
panel is an anti-Myc western blot showing the
expression levels of the fusion proteins. 
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Figure 7
The effect of the ERK2–MEK1 fusion proteins on PC12M cell neurite
outgrowth. Transfections were performed using 10 µg of each plasmid,
except in the ERK2–MEK1-LA experiments, where 100 ng and 1 µg of
plasmid were also used and included in the average. NGF was used at
50 ng/ml. The total number of cells scored in all experiments is
indicated above each bar. Results shown in the first five bars are
averages of 6–12 independent experiments. Results shown in the last
five bars are averages of 2–4 independent experiments.
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activity and did not cause neurite outgrowth in PC12 cells
(Figure 7). Interestingly, KR-ERK2–MEK1 was able to
block NGF-stimulated neurite formation, whereas its
nuclear counterpart was much less effective (Figure 7);
this suggests that KR-ERK2 is a more potent inhibitor of
ERK function when it is in the cytoplasm. This effect
may be because of the formation of unproductive com-
plexes with upstream activators present in the cytoplasm.
RasV12, which has been shown to cause neurite extension
in the absence of NGF [28], produced more neurite
extension than either NGF or ERK2–MEK1-LA in this
system (data not shown). This suggests either that Ras
may activate pathways that promote PC12 cell differentia-
tion other than the ERK1/2 MAP kinase pathway, or that
the activity of endogenous ERKs in response to Ras
exceeds the activity of the fusion protein.
Indirect immunofluorescence of both ERK2–MEK1 and
ERK2–MEK1-LA in PC12M cells shows that
ERK2–MEK1-LA is not only in the nucleus but is also
prominent in the cytoplasm along the developing neurite,
particularly in the dendrites (Figure 8b, compare with
Figure 4b). The wild-type fusion remains cytoplasmic
(Figure 8a). Even at 14 hours after transfection,
ERK2–MEK1-LA can already be observed on the devel-
oping neurite (data not shown). Localization of ERK2 on
dendrites has been reported previously [29]. Active ERK2
is likely to have additional functions in PC12 cell differen-
tiation once the signal has been initiated in the nucleus.
Active nuclear ERK2 is sufficient for cell transformation
Expression of oncogenic Ras or an activated variant of its
effector, Raf1, is sufficient to induce growth and morpho-
logical transformation of NIH3T3 cells. To determine if
constitutively activated ERK2 is sufficient to elicit this
phenotype, we examined the consequences of stable
expression of ERK2–MEK1 and ERK2–MEK1-LA in
focus-formation assays. NIH3T3 cells were transfected
with plasmids encoding ERK2–MEK1, ERK2–MEK1-
LA, ERK2, MEK1-LA or MEK1-R4F (a MEK1 mutant
previously characterized as sufficient to transform immor-
talized rodent fibroblasts). Only ERK2–MEK1-LA
expression resulted in the appearance of foci of growth
and morphologically transformed cells in these assays
(Figure 9 and data not shown). The cytoplasmic fusion
ERK2–MEK1 had no activity in this assay despite
detectable levels of expression in stable lines. In addition,
ERK2 or MEK1-LA alone were not sufficient to induce
foci. Although MEK1-R4F has been shown to transform
cells [18], no foci were induced by this mutant in the cell
line used in this study. Expression of all constructs in
stable transfectants was verified by western blot analysis
(data not shown). Finally, in the context of the NIH3T3
stable cell lines, the two fusion proteins did not have dif-
ferent kinase activities (data not shown) as they did in
1146 Current Biology, Vol 8 No 21
Figure 8
Indirect immunofluorescence of ERK2–MEK1 and ERK2–MEK1-LA in
PC12M cells. (a) ERK2–MEK1 and (b) ERK2–MEK1-LA were stained
48 h following transfection. Both cells shown are typical of cells
expressing high levels of these kinases.
ERK2–MEK1 ERK2–MEK1-LA
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Figure 9
Expression of ERK2–MEK1-LA but not ERK2–MEK1 is sufficient to
transform cells. NIH3T3 cells were transfected with plasmids
expressing the indicated proteins. (a) Plates were fixed and stained
with Geimsa 18 days post-transfection. Foci appear as darkly staining
patches on a monolayer of untransformed contact-inhibited cells.
(b) Stable lines selected in geneticin were plated at low density and
allowed to grow for several days in low serum. Morphology as
visualized by phase contrast microscopy is shown.
Vector
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ERK2–MEK1 ERK2–MEK1-LA
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Current Biology  
transient transfections, yet the nuclear fusion
ERK2–MEK1-LA is still competent to cause transforma-
tion whereas the cytoplasmic fusion is not.
Discussion
Functional characterization of MAP kinase pathways has
depended heavily on the use of constitutively active
upstream activators such as RasV12 and RafBXB in concert
with inhibitors such as the mutant K52R-ERK2, because
no active mutants have been available for MAP kinases
themselves. A significant problem with the use of
upstream components of the pathway is that there may be
multiple effectors in addition to MAP kinase, as has been
demonstrated for Ras [30,31]. Nevertheless, many down-
stream effects of constitutively active Ras have been
attributed at least in part to the ERK1/2 MAP kinases.
Support for this interpretation came from the expression of
kinase-defective or autoinhibitory domains of Raf, MEK1
and ERK1/2 or the use of selective MEK inhibitors, which
block transformation of fibroblasts and neurite extension
in PC12 cells in response to extracellular ligands or to the
expression of oncogenic Ras [2]. These inhibitors indicate
the requirement for ERKs in these processes, but do not
address whether they are sufficient.
Because multiple Ras effector pathways exist, each may
contribute to a differing extent to the actions of Ras [31].
Overexpression of a component of more than one of these
pathways or strong activation of an alternative pathway
may lead to the same phenotypic change. Several exam-
ples supporting this hypothesis have been reported. Acti-
vation of phosphoinositide (PI) 3-kinase is sufficient to
transform fibroblasts [32]. Morphological differentiation of
PC12 cells can occur in response to activation of
SAPK/JNKs [33]. The p21-activated kinase 1 (PAK1) also
causes neurite outgrowth in PC12 cells when directed to
the cell membrane, although this function does not
require PAK1 catalytic activity [34]. Mutant NGF recep-
tors that can still activate ERK do not cause PC12 cells to
differentiate [35] and induction of differentiation by bone
morphogenetic protein does not depend on ERK activa-
tion [36]. Mutational analysis of the platelet-derived
growth factor receptor indicates that stimulation of the
Ras–Raf–ERK pathway is not required to mediate PC12
cell differentiation [37].
We show here that a constitutively active form of ERK2
can be created via fusion of ERK2 to its upstream activa-
tor MEK1. ERK2–MEK1 fusion proteins had no effect on
endogenous ERKs and could be directed to different sub-
cellular compartments. We have ectopically expressed
this constitutively activated variant in cells to explore
whether activation of ERK is sufficient to induce discrete
cellular phenotypes. We demonstrated that
ERK2–MEK1-LA caused phosphorylation of Elk-1 in
vivo and induced transcription via Elk-1 and AP-1. The
fusion protein had no effect on NFκB-driven transcrip-
tion. These results show that active nuclear ERK2 is suffi-
cient to activate well described effectors that lie
downstream of the ERK1/2 MAP kinase pathway.
Although many different upstream components may con-
tribute to transcriptional activation of these factors [38], it
is clear that ERK2 alone can activate transcription when
directed to the nucleus.
We found that active ERK2 was sufficient to cause neurite
outgrowth in PC12 cells when directed to the nucleus.
The subcellular localization of ERK2, in addition to its
activity, was also important; when it was retained in the
cytoplasm, active ERK2 was unable to cause neurite
extension. When expressed in 293 cells, ERK2–MEK1-
LA appeared to be predominantly nuclear. In PC12 cells,
however, ERK2–MEK1-LA was also diffusely localized in
the cytoplasm and strongly localized in the extending
processes. At early times after transfection, ERK2–MEK1-
LA was seen at discrete sites on the membrane that might
develop into processes. This pattern of localization sug-
gests that ERK2 is involved in promoting neurite and den-
drite formation, not only through its actions on gene
transcription but also through effects at the site of neurite
extension. The fact that cytoplasmic ERK2–MEK1 does
not induce neurites is consistent with the idea that at least
some phosphorylation events must occur directly in the
nucleus. Essential ERK2 substrates that contribute to
neurite formation might be present in the plasma mem-
brane. One possibility is the gap junction protein con-
nexin, which is an ERK substrate [39,40]. ERK2 also
phosphorylates a number of cytoskeletal proteins such as
microtubule-associated protein-2 (MAP-2) [41], Tau [42]
and dystrophin [43].
Our second biological assay examined the role of ERK2 in
cell transformation. When transfected into NIH3T3 cells,
constitutively active mutants of MEK1 can induce hall-
marks of cell transformation [18]. Furthermore, cell trans-
formation caused by RasV12 can be blocked by
dominant-negative MEK or ERK [44,45]. The degree of
tumorigenicity obtained with activated Raf or MEK1 iso-
forms is low compared with that obtained with Ras,
however. Other pathways have also been implicated in
cell transformation. For example, the GTPase Rac, which
can cooperate with Raf in activating the ERK pathway
[37], has been shown to cooperate with Raf-1 to induce
cell transformation [46,47]. Thus, although the ERK2
pathway appears to be necessary for cell transformation, its
sufficiency was not clear. We demonstrate that nuclear
active ERK2 is indeed sufficient to induce foci in
NIH3T3 cells. It remains to be determined how active
ERK2 may interact with other cellular pathways to induce
transformation or differentiation. Our active ERK2 con-
structs should allow us to uncover the functions of ERK2
in these and other intracellular signaling pathways.
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Conclusions
Our experiments suggest that fusion of any two kinases
that act sequentially into a single polypeptide may create a
constitutively active kinase. Recently, protein fusion has
been used to successfully reconstitute pathways composed
of sequential activators. For example, self-sufficient elec-
tron-transport chains have been recreated by fusion of
mammalian P450 enzymes with P450 reductases [48].
Also, G-protein-coupled receptors have been fused to Gα
subunits; these fusions are also able to transduce signals
efficiently [49,50]. Thus, this technique may have general
application in the design of active signaling molecules.
Experiments with the ERK2 fusion proteins indicate that
activation of ERK2 is sufficient to induce differentiation
or transformation depending on the cellular context. Sig-
nificant localization in the nucleus is required for these
phenotypic effects, because activated proteins that are
functional in the cytoplasm cannot induce these pheno-
typic changes.
Materials and methods
Plasmids
A 10 amino-acid alternating copolymer of glutamic acid and glycine
was added to the carboxyl terminus of either wild-type or K52R ERK2
using PCR. Also, the following vector amino-acid sequence from
pRSET was present between the end of the linker and the start codon
of MEK1: GGVGSALPGSK. K52R ERK2 has been described [4]. The
stop codons were mutated using the same primer. To introduce an
epitope tag, products were ligated into the mammalian expression
vector mycCMV5. Human MEK1 was the generous gift of N. Ahn.
MEK1 was inserted in-frame after the linker following ERK2 to produce
the fusion protein ERK2–MEK1. All manipulations of fusion proteins
were done at 30°C using TG-1 bacteria to reduce toxicity to the bacte-
ria and the frequency of mutations. The four leucines in the human
MEK1 nuclear export sequence [16] were mutated to alanine using the
double-stranded DNA Quik Change mutagenesis kit (Stratagene) pro-
ducing MEK1-LA. All mutated constructs were verified by DNA
sequencing. MEK1-LA was then inserted both into the vector
mycCMV5 alone to produce mycCMV5 MEK1-LA or in-frame with
either the wild-type or K52R ERK2 linker construct to produce the
fusion proteins ERK2–MEK1-LA and KR-ERK2–MEK1-LA. Human
MEK1 in which S118 and S122 were mutated to aspartate and gluta-
mate respectively (MEK1-SDSE) was the generous gift of N. Ahn. This
MEK was also inserted into the mycCMV5 fusion protein construct to
produce ERK2–MEK1-SDSE. The Gal–Lux reporter (pG5E4D38-Lux),
Gal–Elk, and CMV5-Elk-His6 were the generous gifts of P. Shaw. The
NFκB–Lux and AP-1–Lux reporters were the generous gift of A. Thor-
burn. HA–Rsk and GST–S6 were the generous gifts of J. Blenis and
the GST–S6 protein was purified over glutathione–agarose using stan-
dard techniques.
Cell culture and transfections
HEK 293 cells were grown in Dulbecco’s modified Eagles medium
(DMEM) plus 10% FBS, 1% L-glutamine, 100 U/ml penicillin and
100 µg/ml streptomycin. Dishes of cells (60 mm diameter) that were
60–80% confluent were transiently transfected by calcium phosphate
coprecipitation as described [51]. At 18–24 h after transfection, 293
cells were placed in serum-free medium and incubated for a further
18–24 h before harvesting. PC12M cells were the generous gift of J.
Johnson. PC12M cells were grown in RPMI plus 10% HS, 5% FBS,
1% L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin.
These cells were transfected as above except that 5 h following addi-
tion of precipitate, cells were shocked twice for 1 min with 15% glyc-
erol. PC12 experiments using other transfection methods produced
similar results and similar transfection efficiencies. After transfection,
PC12 cells were grown in the absence or presence of NGF for
48–96 h to allow neurite formation to occur.
Immunoblotting and immunoprecipitation
The antibody against the Myc epitope was from the Cell Culture Center.
This antibody was used at 1:100 for blotting and 10 µg used for
immunoprecipitation. The antibody A249 used to precipitate endoge-
nous ERK1/2 did not recognize the fusion proteins and has been
described [52]. The 12CA5 antibody was used to precipitate and blot
the HA–Rsk. The antibody against doubly phosphorylated ERK1/2
(Promega) was used for western blotting at 1:2000. The antibodies
against Elk-1 and phospho-Elk-1 were from NEB and used as directed
by the manufacturer. In experiments with Elk-1, 10 µg CMV5-Elk-1 was
transfected alone or with 100 ng RasV12, 10 µg ERK2–MEK1 or 10 µg
ERK2–MEK1-LA. Lysates from transfected cells were prepared ~48 h
after transfection in a buffer containing 50 mM Tris pH 8.0, 100 mM
NaCl, 1% NP-40 and 0.5% Triton X-100 and a cocktail of protease and
phosphatase inhibitors. Western blotting was performed with the
enhanced chemiluminescence (ECL) kit (Amersham) using standard
conditions. Immunoprecipitations were performed using 200 µl of
lysates that had previously been checked by western blotting and
shown to contain equivalent amount of expressed proteins. Antibodies
were added and the lysates rocked for 1 h at 4°C. A 50% slurry of
protein-A–Sepharose (Pharmacia) in lysis buffer (30 µl) was added to
each tube for 1 h at 4°C with mixing. Immunoprecipitates were washed
three times with 20 mM Tris pH 8.0, 1 M NaCl and once with kinase
buffer. For immune-complex kinase assays, a mixture containing 20 mM
Tris pH 8.0, 1 mM MgCl2, 100 µM ATP, 25 µCi [32P]ATP and
0.5 mg/ml MBP was added to beads and incubated for 15 min at 30°C.
Samples were then analyzed on SDS–PAGE gels as described [9].
Luciferase reporter assays
HEK 293 cells were transfected with either 1 µg each of Gal–Elk and
Gal–Lux, 1 µg NFκB–Lux, or 1 µg AP-1–Lux with 5 µg mCMV5, 5 µg
ERK2–MEK1, 5 µg ERK2–MEK1-LA or 100 ng RasV12 plus 4.9 µg
mCMV5. Plasmid (1–2 µg) encoding β-galactosidase (β-gal) was also
added to each transfection mixture as a control for transfection effi-
ciency. Cells were placed in medium without serum 18–24 h following
transfection. At 48 h after transfection, cells were harvested in a freshly
made buffer containing 70 mM K2HPO4, 2 mM MgCl2, 1 mM DTT,
50 mM Tris pH 8.0, 0.1% NP-40 and protease inhibitors. Lysates were
then analyzed for β-gal activity [51] and luciferase activity (Promega)
using an Optocomp luminometer. Luciferase activity was normalized to
the β-gal activity. Expression of ERK fusion proteins was equivalent in
each experiment, as determined by western blotting.
Indirect immunofluorescence and neurite scoring
Both 293 and PC12 cells were plated on lysine-coated cover slips.
Transfections were performed as described above. At 48 h after trans-
fection (293) or 72 h after transfection (PC12) cells were fixed using
3.7% formaldehyde and permeabilized with 0.1% Triton X-100. The
anti-Myc antibody was used at a dilution of 1:100 and
diamidinophenylindole (DAPI) was used at 1 µg/ml. Antibody staining
and microscopy were carried out using standard techniques. For
neurite scoring, PC12 cells were transfected with various plasmids
plus a plasmid encoding β-gal as a marker for transfection. At 48–96 h
after transfection, cells were fixed with warm 3.7% formaldehyde and
stained for β-gal activity. Blue cells were counted and the number of
cells with neurites was scored. In order to be counted the neurite had
to be longer than the cell body. The percentage of cells with neurites
was normalized to a vector-alone control and expressed as the fold
increase in neurite formation.
Foci formation and stable transfections
NIH3T3 cells were transfected by the calcium phosphate method as
described [30] using 1 µg tester DNA together with 1 µg pDCR car-
rying the NeoR gene. At 2 days post-transfection, each plate was
split 1:4 into two plates containing DMEM plus 5% calf serum for
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focus-formation assays, and two plates containing DMEM plus 10%
calf serum and 0.5 mg/ml G418 (Life Technologies), to select for
stable transfectants. Focus assays were fixed (10% formaldehyde)
and stained with Geimsa 18 days post-split to visualize the foci of
transformed cells.
Supplementary material
Figures showing western blots of the fusion proteins, phosphatase inac-
tivation of the fusion proteins, and the inactivity of ERK2 when fused to a
kinase-dead MEK1 are published with this paper on the internet.
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S1Supplementary material
Figure S1
The ERK2–MEK1 fusions are expressed as full-length proteins with no
breakdown products. The fusion proteins indicated were transiently
expressed in 293 cells and a western blot of lysates was performed
with the anti-Myc antibody. (The ERK2–MEK1-I fusion protein in the
right-hand lane was not part of these studies.) ERK2 was also
transfected as a size marker for possible breakdown products. No
smaller molecular weight products were observed. 
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Figure S2
Phosphatase 1B (PTP1B) can inactivate ERK2–MEK1 fusion proteins
but the fusions are quickly reactivated. Either ERK2–MEK1 or
ERK2–MEK1-LA were immunoprecipitated from 293 cell lysates and
incubated in the absence or presence of 86 µg/ml purified PTP1B for
30 min. Reactions were stopped by the addition of vanadate and
beads were washed with kinase reaction buffer plus vanadate. MBP
kinase assays were then performed for either 1 min or 15 min. Purified
phosphorylated ERK2 (phospho-ERK2) was used as a positive control. 
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Figure S3
Kinase-dead MEK1 (MEK1-KM) cannot activate ERK2 in a fusion
protein. ERK2 was fused to MEK1-KM and expressed in 293 cells.
Although the fusion protein was expressed well, as indicated by (a) an
anti-Myc western blot, (b) immunoprecipitated ERK2–MEK1-KM did
not have MBP kinase activity any greater than a vector-alone control.
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